Comparison of Levetiracetam and sodium Valproate in the prevention of migraine: a randomized clinical trial study
Keywords:Levetiracetam, Migraine, Sodium valproate
Background: Sodium valproate is an anti-seizure drug used for prophylactic use of migraine headaches. Despite the efficacy of this drug due to complications that cause some patients to not tolerate the drug. The purpose of this study was to Comparison of levotiracetam and Sodium valproate in migraine prophylaxis.
Methods: This is a clinical trials study. 100 migraineurs who referred to the Alavi neurology clinic and indicated the onset of prophylaxis of migraine were studied in two groups of 50, one of which was a group of levetiracetam and another group of sodium valproate Received. Patients received daily 500mg of drug for 3 months and the effect of the drug on the number of attacks, severity of attacks, and MIDAS score was measured. Collected data analyzed by statistical methods in SPSS version 19. P<0.05 was considered as significant.
Results: In both cases, significant improvement was observed in the number of attacks, severity and MIDAS score. In all of the criteria, levetiracetam and sodium valproate were almost identical, except for reducing the number of headache attacks that had a significantly in levothyramine group less than sodium valporoste group (P = 0.0001).
Conclusions: This study showed that levothyramineacetamin can be used as a good alternative in those who do not tolerate sodium valproate.
Boes CJ, Capobianco DJ, Cutrer FM, Dodick DW, Eross EJ, Swanson JW, et al. Neurology in clinical practice. 5th Ed Butterworth, Heinemann; 2008:2026-2042.
Mohammadianinejad SE, Babaei M, Nazari P. The Effects of Exposure to Low Frequency Electromagnetic Fields in the Treatment of Migraine Headache: A Cohort Study. Electron Physician. 2016 Dec 25;8(12):3445-9.
Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse Epidemiology and impact on quality of life. Neurology. 2004 Apr 27;62(8):1338-42.
Friedman DI, De Ver Dye T. Migraine and the environment. Headache: The J Head and Face Pain. 2009 Jun 1;49(6):941-52.
Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clinical therapeutics. 2003 Oct 1;25(10):2506-38.
Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database of systematic Review 2009;(2):CD003225.
Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004 Feb 25;291(8):965-73.
Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. The J Heada and Pain. 2011 Jun 1;12(3):361-8.
Landmark CJ. Antiepileptic drugs in non-epilepsy disorders Relations Between mechanisms of action and clinical efficacy. CNS Drugs. 2008,22(1):27-47.
Eiland LS, Jenkins LS, Durham SH. Pediatric migraine: Pharmacologic agents for prophyloxis. Ann Pharmaco ther. 2007,41:118-90.
Zwab A, Canmady J. Safe use of Sodium valproate. Neurology. 2014Aug4;37(8):124-6.
Gallai V, Alberti A, Rossi C, Coppola F, Gallai B, et al. An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. J Headache Pain. 2003;4:92-6.
Sadeghian H, Motiei-Langroudi R. Comparison of Levetiracetam and sodium Valproate in migraine prophylaxis: A randomized placebo-controlled study. Ann Indian Acad Neurol. 2015;18(1):45-8.
Homam M, Farajpour A, Khadem S, Mostafavian Z. The Experiential Comparison of Levetiracetam Efficacy in Migraine Headache with Sodium Valproate. CJNS. 2016;2(5):42-9.
Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008 Nov 1;28(11):1170-78.
Verma A, Srivastava D, Kumar A, Singh V. Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in Northern India. Clinical neuro Pharmacol. 2013 Nov 1;36(6):193-7.